RTI Talking With Potential Acquirer, Seeking Clearance For Xenograft Implant
This article was originally published in The Gray Sheet
Executive Summary
Regeneration Technologies, Inc.'s compliance with FDA's Good Tissue Practice regulations may have piqued the interest of a potential acquirer or strategic partner with whom the biologics manufacturer apparently is in discussions
You may also be interested in...
Tissue Product Distributors Disappoint RTI, May Prompt Sales Autonomy
Regeneration Technologies, Inc. (RTI) will consider creating an independent sales force after Medtronic placed fewer orders during Q1, causing RTI spinal revenue to drop by nearly half
Tissue Product Distributors Disappoint RTI, May Prompt Sales Autonomy
Regeneration Technologies, Inc. (RTI) will consider creating an independent sales force after Medtronic placed fewer orders during Q1, causing RTI spinal revenue to drop by nearly half
FDA Completes “Risk-Based” Reg Trilogy With Good Tissue Practices
Manufacturers of tissue products have until May 25 to implement a comprehensive tissue tracking system under the 1Good Tissue Practice (GTP) regulations finalized Nov. 18